Multi-center case series study of lung injury associated with novel drugs for rheumatoid arthritis treatment
Project/Area Number |
19590530
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Applied pharmacology
|
Research Institution | Tokyo Medical and Dental University |
Principal Investigator |
KOIKE Ryuji Tokyo Medical and Dental University, 医学部附属病院, 准教授 (50250220)
|
Co-Investigator(Kenkyū-buntansha) |
HARIGAI Masayoshi 東京医科歯科大学, 医歯学総合研究科, 客員教授 (20238207)
MIYASAKA Nobuyuki 東京医科歯科大学, 医歯学総合研究科, 教授 (30157622)
|
Project Period (FY) |
2007 – 2009
|
Project Status |
Completed (Fiscal Year 2009)
|
Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2009: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2008: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2007: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
Keywords | 医薬品副作用 / 抗リウマチ薬 / 関節リウマチ / ニューモシスチス肺炎 / 薬剤性肺炎 / 薬剤性肺障害 / エタネルセプト / タクロリムス / データベース / 間質性肺炎 / インフリキシマブ / 肺合併症 / レフルノミド |
Research Abstract |
We have studied pulmonary complications associated with novel drugs approved for rheumatoid arthritis treatment recently. We have focused on the Pneumocystis pneumonia under infliximab or etanercept treatment and drug-induced pneumonia under tacrolimus treatment. And we have constructed and arranged the database of Japanese rheumatoid arthritis patients, which is essential for the research of adverse reactions induced by anti-rheumatic drugs.
|
Report
(4 results)
Research Products
(47 results)
-
-
-
[Journal Article] Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis2009
Author(s)
Koike R, Harigai M, Atsumi T, Amano K, Kawai S, Saito K, Saito T, Yamamura M, Matsubara T, Miyasaka N.
-
Journal Title
Mod Rheumatol 19
Pages: 351-7
NAID
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-